Dr. John Mathews
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 18
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 390
Licensed in Texas since 2014, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
TX license Q1216 (first issued 2014; active) -
Internal Medicine Physician
TX license BP1-0031780
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Medical City Dallas Hospital Dallas, TX
Medical groups
- Texas Oncology PA (1,014 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 390
- Services billed
- 45,907
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 2,017 | 180 |
| Blood test, comprehensive group of blood chemicals | 892 | 154 |
| Magnesium level | 890 | 154 |
| Lactate dehydrogenase (enzyme) level | 884 | 154 |
| Injection, dexamethasone sodium phosphate, 1 mg | 605 | 26 |
| Phosphate level | 578 | 113 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 566 | 130 |
| Established patient office or other outpatient visit, 30-39 minutes | 540 | 141 |
| Insertion of needle into vein for collection of blood sample | 415 | 117 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 330 | 90 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Dallas, TX | 243 |
| Pantoprazole Sodium Other prescribers in Dallas, TX | 134 |
| Prednisone Other prescribers in Dallas, TX | 89 |
| Gabapentin Other prescribers in Dallas, TX | 67 |
| Eliquis (apixaban) Other prescribers in Dallas, TX | 56 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Dallas, TX | 47 |
| Potassium Chloride Other prescribers in Dallas, TX | 44 |
| Amlodipine Besylate Other prescribers in Dallas, TX | 41 |
| Lantus Solostar (insulin glargine,hum.rec.anlog) Other prescribers in Dallas, TX | 37 |
| Furosemide Other prescribers in Dallas, TX | 37 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 28 payments worth $655 in total to this clinician.
| AbbVie Inc. | $198 |
|---|---|
| Janssen Biotech, Inc. | $128 |
| Janssen Scientific Affairs, LLC | $86.22 |
| Astellas Pharma US Inc | $60.35 |
| Daiichi Sankyo Inc. | $49.95 |
| Kite Pharma, Inc. | $47.53 |
| Takeda Pharmaceuticals U.S.A., Inc. | $27.45 |
| Geron Corporation | $25.80 |
| Food and Beverage | $488 |
|---|---|
| Education | $167 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Dec 16, 2025 | Education IMBRUVICA · ONCOLOGY · in-kind | $99.00 |
| AbbVie Inc. Jan 16, 2025 | Education CREON · ENDOCRINOLOGY · in-kind | $9.65 |
| AbbVie Inc. Feb 17, 2025 | Education CREON · ENDOCRINOLOGY · in-kind | $9.65 |
| AbbVie Inc. Apr 8, 2025 | Education CREON · ENDOCRINOLOGY · in-kind | $9.65 |
| AbbVie Inc. Aug 20, 2025 | Education CREON · ENDOCRINOLOGY · in-kind | $9.65 |
| AbbVie Inc. Sep 16, 2025 | Education CREON · ENDOCRINOLOGY · in-kind | $9.65 |
| AbbVie Inc. Nov 10, 2025 | Education CREON · ENDOCRINOLOGY · in-kind | $9.65 |
| AbbVie Inc. Dec 15, 2025 | Education CREON · ENDOCRINOLOGY · in-kind | $9.65 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $26,843 in research payments for these studies, mostly to the institutions running them.
- Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.